IFRX
InflaRx (IFRX)
$89
About InflaRx (IFRX)
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Details
Daily high
$0.90
Daily low
$0.83
Price at open
$0.84
52 Week High
$2.77
52 Week Low
$0.71
Market cap
60.1M
Dividend yield
0.00%
Volume
638,597
Avg. volume
636,123
P/E ratio
-.85
InflaRx News
Details
Daily high
$0.90
Daily low
$0.83
Price at open
$0.84
52 Week High
$2.77
52 Week Low
$0.71
Market cap
60.1M
Dividend yield
0.00%
Volume
638,597
Avg. volume
636,123
P/E ratio
-.85